Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
As many in the field have said before, what we really need are antifungals with a truly novel MoA, not minor changes to well-established classes.[1] There is a shortage of new antifungals for invasive disease. Small improvements in PK will hardly Continue reading The Antifungal Landscape – 2
Some newer azoles are still in development, but most only target candidiasis. Many years ago we saw development of nikkomycin (Nik Z), a drug mainly for coccidioidomycosis (Valley Fever). It has no appreciable activity against candida or aspergillus. Then there Continue reading The Antifungal Landscape – 1
The early work on the organism and the toxoid vaccine reads like the ‘Who Is Who’ of microbiology: Klebs, Loeffler, Koch, Roux, Yersin, Behring, Kitasato, Schick, and T. Smith were all involved in bringing this deadly disease under control. In Continue reading About DIPHTHERIA
David Larwood, CEO of VFS, summed it up at the Cocci FDA workshop in 2020: “When the market opportunity is limited, finding investment becomes the key issue”. He mentioned other problems as well: “Very low patient numbers for disseminated disease, Continue reading Draft FDA Guidance for COCCIDIOIDOMYCOSIS
Regulatory and development status of Olorofim, a novel antifungal. Continue reading OLOROFIM in a TIGHT SPOT